Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Cash & Equivalents (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Cash & Equivalents data on record, last reported at $72.7 million in Q2 2025.

  • For Q2 2025, Cash & Equivalents changed N/A year-over-year to $72.7 million; the TTM value through Jun 2025 reached $72.7 million, changed N/A, while the annual FY2024 figure was $71.3 million, 19.3% down from the prior year.
  • Cash & Equivalents reached $72.7 million in Q2 2025 per ARQT's latest filing, up from $71.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $409.4 million in Q2 2021 and bottomed at $53.6 million in Q4 2022.
  • Average Cash & Equivalents over 5 years is $132.2 million, with a median of $88.4 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: soared 82.77% in 2021, then crashed 84.97% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $96.4 million in 2021, then crashed by 44.38% to $53.6 million in 2022, then soared by 64.8% to $88.4 million in 2023, then fell by 19.3% to $71.3 million in 2024, then increased by 1.97% to $72.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $72.7 million in Q2 2025, $71.3 million in Q4 2024, and $134.9 million in Q3 2024.